Kava

Information

Kava is a root from the South Pacific (Piper methysticum) used for centuries in Fiji, Vanuatu, Samoa, and Tonga as a social and ceremonial drink. In supplement form, it's taken for one main reason: to take the edge off anxiety and tension without the brain-fog of a benzodiazepine or the wait time of an SSRI. People reach for it before social events, around stressful work periods, or in the evenings to wind down and sleep better.

The practical pitch: kava acts on the same calming brain system as Valium and Xanax (GABA), but through a different door, so it doesn't carry the same dependency profile. The catch is that quality matters enormously. Get it right (water-extracted root from a noble cultivar) and it's well tolerated. Get it wrong (cheap extracts using leaves, stems, or solvents) and it's the supplement most associated with liver injury in Western markets.

Deep-dive

How it actually works

The active compounds in kava are a family of about 18 fat-soluble molecules called kavalactones, with kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, and desmethoxyyangonin doing most of the work. The classic theory was that kava simply enhances GABA, the brain's main calming neurotransmitter. Sydney researchers in 2016 confirmed that kavain directly potentiates GABA-A receptors, but importantly, it does this at a different binding site than benzodiazepines, which is why flumazenil (the benzo-reversal drug) doesn't block its effects. This matters practically because it's likely the reason kava doesn't produce the same tolerance, dependence, or rebound anxiety that long-term benzodiazepine use causes.

Kavalactones also do other things. They weakly inhibit monoamine oxidase B, block sodium and calcium channels (contributing to muscle relaxation), and inhibit noradrenaline reuptake in the prefrontal cortex, which may explain why some users report feeling calm but mentally clear rather than dulled. A systematic review of cognition trials found that, unlike benzodiazepines, kava generally doesn't impair cognitive function at therapeutic doses, with some acute studies actually showing modest improvements in visual attention and working memory.

The clinical evidence, honestly

The early evidence was strong. Multiple placebo-controlled trials using the German standardised extract WS 1490 showed significant reductions in anxiety scores over 4 to 24 weeks at doses of 150 to 300 mg of extract daily. A 2013 RCT by Sarris and colleagues using an aqueous extract at 120 to 240 mg of kavalactones showed kava beat placebo in generalised anxiety disorder, with a 26% remission rate versus 7% for placebo and a moderate-to-large effect size.

Then things got murkier. The same research group ran a larger, longer 16-week trial in 2020 and kava was no better than placebo for diagnosed GAD, and liver enzyme abnormalities were more common in the kava group (though not severe). The honest read is this: kava appears to work for situational, mild-to-moderate anxiety in non-clinical populations, but for people with full-blown chronic GAD, it's probably not a strong enough tool on its own. It's a stress-tension reducer, not an antidepressant or a frontline GAD treatment.

For women specifically

Most kava trials have included women (often the majority of participants), but few have analysed sex differences directly. The most relevant study is Cagnacci's 2003 trial in perimenopausal women, where 100 to 200 mg of kava daily for 3 months significantly reduced anxiety, depression, and overall climacteric symptoms compared to calcium-only controls. This is genuinely useful: anxiety often spikes during perimenopause as oestrogen fluctuates and destabilises GABA tone, and kava is one of the few non-hormonal options with direct evidence in this group.

A practical note for women: kava inhibits CYP1A2, CYP2D6, and CYP3A4, which can raise blood levels of drugs metabolised by these enzymes. Hormonal contraceptives are largely metabolised by CYP3A4, and while no trial has shown contraceptive failure with kava, the theoretical interaction warrants caution. Interestingly, the Sarris GAD trial reported that women on kava experienced increased sexual desire, with the authors attributing this to anxiety reduction rather than a direct hormonal effect.

The liver question, properly unpacked

In the early 2000s, dozens of cases of severe liver injury, including some requiring transplant, were reported in Europe and the US, leading to bans in Germany, Switzerland, France, and the UK. Thorough investigation by Teschke and colleagues revealed that the issue was not kava itself but the raw material. Western manufacturers were using cheaper plant parts (leaves, stems, peelings) instead of the rhizome and roots, non-noble cultivars, and ethanol or acetone extraction methods that pulled out hepatotoxic flavokavains, particularly flavokavain B. Glutathione, which neutralises these compounds, is present in traditional water-extracted preparations but stripped out by solvent extraction.

There's also a genetic angle. Roughly 10 to 21% of people of European descent are CYP2D6 poor metabolisers, compared to about 1% of Pacific Islanders, which may partly explain why centuries of Pacific consumption produced few liver problems while Western use produced a cluster of cases. Combined with concurrent alcohol, paracetamol, or other hepatotoxic drugs, the risk of an unlucky reaction goes up.

The practical takeaway: the liver risk with properly produced, water-extracted noble kava root taken at sensible doses is real but low. The liver risk with cheap solvent-extracted products of unknown origin is meaningfully higher. Don't drink alcohol with it, don't combine it with paracetamol around the same time, and don't stack it with other hepatotoxic supplements.

Limits of the evidence

Most trials are short (4 to 16 weeks), use German standardised extracts that aren't necessarily what's on shelves now, and rarely report on whether kava actually outperforms simpler interventions like exercise or basic sleep hygiene. The kava-versus-benzodiazepine comparison studies are old and small. We don't have good data on long-term daily use beyond 6 months, and we don't have great data on how kava interacts with SSRIs, which is the most relevant real-world question for many users.

Dosage

Standardised extract (capsules): 100 to 300 mg of an extract standardised to 30 to 70% kavalactones, taken once or twice daily. This works out to roughly 70 to 250 mg of kavalactones per day.

Traditional water extract (drinks/instant kava): 1 to 3 servings per session, with each serving typically delivering 50 to 100 mg of kavalactones. Most users feel effects within 15 to 30 minutes.

For acute use (before a stressful event, social anxiety, sleep): a single 100 to 200 mg kavalactone dose 30 to 60 minutes before is the practical sweet spot.

For ongoing daily use (chronic mild anxiety, perimenopausal mood support): 120 to 240 mg of kavalactones per day, divided. Women in the perimenopausal trial used 100 to 200 mg/day with good results.

Take on an empty stomach. Pharmacokinetic data shows that food significantly reduces absorption of kavalactones.

Don't exceed 250 mg of kavalactones per day for routine use, and cap continuous daily use at around 1 to 2 months before taking a break of at least a few weeks. This is the German Commission E guideline and aligns with the safety data.

What to buy: water-extracted (not ethanol or acetone) noble cultivar (Borogu, Borongoru, Mahakea, Moi) made from peeled rhizome and root, ideally lab-tested for kavalactone content and flavokavain B. Avoid anything labelled "kava leaf," "aerial parts," or "full-spectrum" without specifying root only.

Don't combine with: alcohol, benzodiazepines, opioids, sleep medications, paracetamol around the same time, or other sedating supplements (valerian, high-dose magnesium glycinate at night is fine; high-dose CBD might be too much).

Here's what you can expect

Most people feel kava within 15 to 45 minutes of an empty-stomach dose. The subjective experience is distinctive: a physical settling in the body (jaw, shoulders, chest), reduced mental chatter, and a sense of social ease, but without the cognitive blunting of alcohol or benzodiazepines. People often describe it as feeling "sober but calm." Effects last 2 to 4 hours.

With traditional water-prepared kava, you'll also notice a numbing sensation on the tongue and lips, a bitter, earthy taste, and sometimes a mild euphoria at higher doses. Capsule-form extracts give you the anxiety reduction without the oral numbness or social ritual.

For anxiety, the acute effect is usable from the first dose. For sustained reduction in baseline anxiety, the German trials showed that the meaningful separation from placebo typically appears around week 4 to 8 of consistent dosing. If you're not noticing anything after 4 weeks at a proper dose with a quality product, it's probably not your tool.

What you shouldn't expect: a stimulant-like clarity, an antidepressant lift in mood, or a fix for severe panic disorder or major depression. Kava is a stress-tension dial, not a personality changer.

Side effects & risks

At sensible doses with quality product, side effects are mild and uncommon. The most frequently reported are stomach upset, mild headache, and drowsiness, which is why most users avoid driving for a few hours after a dose. Larger doses can cause ataxia (unsteady walking), visual disturbances, and slowed reaction time. These are dose-dependent and reversible.

Chronic heavy use, mostly documented in traditional Pacific drinkers consuming far above supplemental doses, can produce kava dermopathy: a dry, scaly, fish-scale-like skin condition that resolves within weeks of stopping. Heavy chronic use has also been associated with lower platelet counts, lower lymphocytes, and elevated GGT. None of this is relevant to someone taking 200 mg of kavalactones a few evenings a week, but it tells you the ceiling.

The big one is liver injury. With properly produced water-extracted noble root at sensible doses, the risk is low but not zero, and it appears to be idiosyncratic (rare, unpredictable, not strictly dose-related). The risk goes up significantly with solvent-extracted products, products containing leaves or stems, concurrent alcohol or paracetamol, daily use beyond 1 to 2 months, and existing liver disease.

Don't use kava if you have any liver condition, are pregnant or breastfeeding, are taking benzodiazepines or other sedatives, are on Parkinson's medication (kava can worsen extrapyramidal symptoms), or are scheduled for surgery within 2 weeks (it potentiates anaesthesia and may affect bleeding). Be cautious if you're on hormonal contraceptives, antidepressants, or any drug metabolised by CYP3A4, CYP1A2, or CYP2D6.

Kava is restricted or banned in some countries (notably parts of Europe) and legal in others. Quality and labelling vary widely.